Company intelligence / Profile preview
Aexon Labs
Lewes, Delaware, United Statesaexonlabs.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
The company has published a recent patent (WO2024115797) for dual non-sulfonamide orexin receptor agonists demonstrating stable pharmacological profiles, improved safety (non-sulfonamide classification to reduce side effects), and early promising in vitro data for narcolepsy and neurodegenerative disease. The compounds address both symptomatology and underlying neuronal destruction (e.g., cathepsin inhibition), but none are yet in clinical trials.
- Therapeutic areas
- Neurology
- Modalities
- Small moleculeChemical drug
- Industry
- Biotech
02
Drug pipeline
7 assets6 more assets in the full pipeline.
03
Partnerships
NLS Pharmaceutics (Swiss public biopharma; global licensing and development agreement for dual orexin agonist platform)
Beyond the preview
Go deeper on Aexon Labs.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Aexon Labs.